Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs EPAM Systems Inc (EPAM) Price & Performance

DexCom, Inc.Trade
EPAM Systems IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs EPAM Systems Inc — how do they compare? DexCom, Inc. trades at $89.08 (market cap $33.79B), while EPAM Systems Inc trades at $98.39 (market cap $5.15B). The key difference: DexCom, Inc. is far larger — about 6.6× EPAM Systems Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.

DXCMEPAM
Market Cap
$33.79B$5.15B
Sector
HealthTechnology
52-Week High
$89.53$221.40
52-Week Low
$54.84$76.04
Enterprise Value
$33.24B$4.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.

The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.

EPAM Systems Inc

EPAM trades at $98.20, up 0.85% on the day, but remains in a bearish technical trend with support near $96 and resistance at $99. The company reported strong Q2 2026 earnings of $3.38 per share, beating estimates, but lowered its full-year revenue guidance due to slower North American growth. Valuation metrics appear attractive with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net income margin of 7.15%.

The outlook is mixed: analyst consensus is bullish with a $117.27 price target, but near-term headwinds from reduced revenue guidance and bearish technical signals pose risks. The stock offers value based on fundamentals, but investor sentiment is cautious following the guidance cut, requiring close monitoring of North American demand trends and AI partnership execution for sustained upside.

Returns comparison

Trailing returns across standard periods

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM